Air quality remains concerning in parts of Peninsular Malaysia
Malaysia's Department of Environment website reported unhealthy Air Pollutant Index readings in multiple locations as of 11am on July 20.
PETALING JAYA — Air quality in several parts of Peninsular Malaysia remains concerning, with the Department of Environment (DOE) website reporting unhealthy Air Pollutant Index (API) readings in multiple locations as of 11am on July 20.
Nilai in Negri Sembilan recorded the highest API at 160, placing it firmly in the 'unhealthy' category.
This was followed by Banting in Selangor, with an API of 153, also categorised as unhealthy.
Putrajaya recorded an API of 111, while Temerloh in Pahang posted a reading of 104.
Both areas fall within the 'unhealthy for sensitive groups' category, indicating that individuals with respiratory issues, the elderly, and young children may face adverse effects.
In the Klang Valley and surrounding areas, air quality remained moderate.
Kuala Lumpur recorded an API of 96, followed by Alor Gajah in Melaka at 94.
Top stories
Swipe. Select. Stay informed.
Singapore 1 in 3 vapes here laced with etomidate; MOH working with MHA to list it as illegal drug: Ong Ye Kung
Singapore HSA extends hotline hours, launches new platform to report vaping offences
Asia Tearful relatives await news of victims in Vietnam boat capsize
Singapore ComfortDelDro to discipline driver who flung relative's wheelchair out of taxi
Multimedia How to make the most out of small homes in Singapore
Asia Over 380,000 people affected by autogate glitch at JB checkpoint over 2 days
Singapore Minor Issues: Why I didn't send my daughters to my brand-name primary school
Opinion I thought I was a 'chill' parent. Then came P1 registration
Port Dickson and Seremban, both in Negri Sembilan, recorded readings of 92 and 91, respectively.
Bukit Rambai and Bandaraya Melaka followed closely with API readings of 89 and 88.
Over in East Malaysia, air quality remained moderate as well.
In Sabah, Kota Kinabalu recorded an API of 59, while Keningau posted 58.
In Sarawak, Miri recorded a reading of 62, Bintulu 61, and Kuching 55.
According to the DOE, an API reading of 0–50 is considered 'good', 51–100 is 'moderate', 101–200 is 'unhealthy', 201–300 is 'very unhealthy', and anything above 300 is categorised as 'hazardous'. THE STAR/ASIA NEWS NETWORK
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
AsiaOne
2 hours ago
- AsiaOne
HSA seizes 54 vape pods during raid of 16-year-old boy's home, etomidate found in some, Singapore News
The Health Sciences Authority (HSA) seized 54 vape pods from a teen's home, and tests found that some of them contained etomidate. The 16-year-old was one of two that had allegedly vaped in a private-hire car while travelling along Bukit Timah Expressway on May 18. The driver of the vehicle then reported the incident to traffic police, who seized two e-vaporisers from one of the two teens, the authority said in a statement. Four days later, HSA officers raided the homes of the two teens, seizing 54 vape pods and three e-vaporisers from the same person caught with vapes in the car. The other teen had no e-vaporisers or related items in his home, HSA said, adding that both are assisting with investigations. More than 2,500 reports of vaping-related offences in first half of 2025: HSA There has been an increase in public feedback regarding vaping-related offences since 2024, the authority said. While over 3,000 reports were made in the whole of 2024, more than 2,500 reports have already been made in the first half of 2025, the authority revealed. "In addition, we noted a considerable increase in the number of social media postings showing others vaping in the public," HSA stated. "Through these public feedback and social media postings, HSA was able to use them as an additional source of surveillance data to intensify our enforcement activities." It will also be enhancing reporting channels beginning on Monday (July 21), with an expansion of the hotline service (66842036 or 66842037) to operate from 9am to 9pm throughout the week. A new online reporting platform will also allow more convenient access for the public to report illegal e-vaporiser activities. At a doorstop interview on vaping enforcement on Sunday (July 20), Health Minister Ong Ye Kung highlighted concerns the Ministry of Health (MOH) and Ministry of Home Affairs (MHA) have regarding the rise in etomidate-laced vaping. "As an interim measure, we are working with MHA to list etomidate as a Class C drug under the Misuse of Drugs Act (MDA)," he said. "Today, e-vaporisers are no longer just used for the delivery of nicotine," Ong said. "They are being used to deliver a range of substances and what we are seeing is the delivery of etomidate." He shared that etomidate, a controlled substance under the Poisons Act, is "damaging" when consumed via vapes. Ong explained that etomidate can cause permanent organ failure and hallucinations, and that the substance has been linked to fatal traffic accidents and other unnatural deaths. Among 100 vapes that were seized and taken for testing, a third of them were positive for etomidate, he added. Under MDA, users of etomidate will be "treated no differently" from those who consume hard drugs and narcotics such as cannabis or cocaine, Ong stated. This change will take a few weeks to come into effect, he said, urging those who use etomidate-laced vapes to stop as soon as possible. [[nid:720375]] khooyihang@
Straits Times
4 hours ago
- Straits Times
Britain battles anti-vax misinformation after child's death
Find out what's new on ST website and app. A British influencer with more than 200,000 followers on Instagram posted a video denying the child died from measles. LONDON - A child's death from measles has sparked urgent calls from British public health officials to get children vaccinated, as the UK faces an onslaught of misinformation on social media, much of it from the United States. Measles is a highly infectious disease that can cause serious complications. It is preventable through double MMR (measles, mumps and rubella) jabs in early childhood. Health Secretary Wes Streeting on July 14 confirmed to parliament that a child had died in the UK of measles. No details have been released, but British news outlets The Sunday Times and Liverpool Echo reported the child had been severely ill with measles and other serious health problems in Alder Hey hospital in the north-western city of Liverpool. Anti-vaxxers quickly posted unconfirmed claims about the death on social media. One British influencer, Ms Ellie Grey, who has more than 200,000 followers on Instagram, posted a video denying the child died from measles. 'Measles isn't this deadly disease... it's not dangerous,' she said. Ms Grey criticised Alder Hey hospital for posting a video 'really, really pushing and manipulating parents into getting the MMR vaccine'. Her video was reposted by another British influencer, Ms Kate Shemirani, a struck-off ex-nurse who posts health conspiracy theories. 'No vaccine has ever been proven safe and no vaccine has ever been proven effective,' Ms Shemirani claimed falsely. Liverpool's public health chief Matthew Ashton attacked those 'spreading misinformation and disinformation about childhood immunisations' in the Echo newspaper, saying 'they need to take a very long, hard look at themselves '. 'For those of you that don't know, measles is a really nasty virus,' he said in a video, adding that the jab is a way of 'protecting yourself and your loved ones'. Alder Hey hospital said it has treated 17 children with measles since June 2025 . It posted a video in which a paediatric infectious diseases consultant Andrew McArdle, addresses measles 'myths', including that the MMR jab causes autism. This false claim comes from a debunked 1998 study by a British doctor Andrew Wakefield, who was later struck off. But it sparked an international slump in vaccinations. 'Lingering questions' Dr Benjamin Kasstan-Dabush, a medical anthropologist at the London School of Hygiene and Tropical Medicine, told AFP there are still 'lingering questions around the Wakefield era'. He talked to parents who had delayed vaccinating their children, finding reasons included life events and difficulty getting health appointments, but also misinformation. 'We're obviously talking about a different generation of parents, who might be engaging with that Wakefield legacy through social media, through the internet, and of course through Kennedy,' he said. US President Donald Trump appointed Robert F. Kennedy Jr as health secretary despite his promotion of anti-vaccine conspiracy theories. Mr Kennedy fired all 17 experts on a key vaccine advisory pane l and appointed a scientist who warned against Covid jabs. In the US , 'misinformation is being produced in the highest echelons of the Trump administration', which 'circulates across the internet', Dr Kasstan-Dabush said. In a sign of how narratives spread, a Telegram group airing conspiracies called Liverpool TPR, which has around 2,000 members, regularly posts links to anti-vaccine group Children's Health Defence once chaired by Mr Kennedy. In the past few weeks the UK Health Security Agency has amplified its social media coverage on vaccinations, a spokesman said. In a video in response to the reported death, Dr Vanessa Saliba, a consultant epidemiologist, explained the MMR jab protects others, including those 'receiving treatment like chemotherapy that can weaken or wipe out their immunity'. Take-up of the MMR jab needs to be 95 per cent for herd immunity, according to the World Health Organisation. The UK has never hit this target. In Liverpool, uptake for both doses is only around 74 per cent and below 50 per cent in some areas, according to Mr Ashton, while the UK rate is 84 per cent . After Mr Wakefield's autism claims, confirmed measles cases topped 2,000 in England and Wales in 2012 before dropping. But in 2024 , cases soared again. The same trend is happening in other countries. Europe in 2024 reported the highest number of cases in over 25 years , and the US has recorded its worst measles epidemic in over 30 years. Canada, which officially eradicated measles in 1998, has registered more than 3,500 cases in 2025 . A Canadian infectious diseases doctor, Alon Vaisman, told AFP: 'You're fighting against the wall of disinformation and lies.' AFP
Straits Times
10 hours ago
- Straits Times
Trial of new dengue vaccine begins recruitment for child participants in Singapore
Find out what's new on ST website and app. The study's lead investigator in Singapore, Assistant Professor Chia Po Ying (left), and Dr Zhong Youjia, another investigator on the study. SINGAPORE – A phase three clinical trial is being conducted here to evaluate the safety and efficacy of a new quadrivalent dengue vaccine in children aged two to 17. Developed by US-based pharmaceutical firm MSD, V181 is a single-dose vaccine that aims to provide protection against all four serotypes, or strains, of the dengue virus. Phase three clinical trials are typically the last stage of testing before a drug's details and clinical trial results are submitted to the regulatory authorities for approval. The study's lead investigator in Singapore, Assistant Professor Chia Po Ying, noted that V181 is a live-attenuated vaccine, which uses weakened versions of all four dengue serotypes. 'Using the weakened forms of all these four dengue serotypes stimulates a human immune response to create protection against dengue infection in future,' said Prof Chia, who also heads the National Centre for Infectious Diseases Research Office. The new study here hopes to recruit at least 700 healthy children between the ages of two and 17, including both those who have previously contracted dengue and those who have never had the disease, said Dr Zhong Youjia, another investigator on the study. This particular study focuses on children as they are more vulnerable to dengue and are also at a greater risk of severe infection, said the associate consultant at National University Hospital's (NUH) Khoo Teck Puat – National University Children's Medical Institute. Side effects from the vaccine have been mild and short-lived, said Prof Chia, noting that they include muscle aches and fatigue. Children enrolled in the study will be randomly chosen to get a single shot of either the vaccine or a placebo. 'There have been no serious adverse events linked to vaccination with V181 to date, and the previous trials actually have shown a very good and favourable safety profile,' Prof Chia said. In Singapore, the study is being conducted at NUH and Tan Tock Seng Hospital, which have already started recruiting participants. Only a handful of children have been recruited so far for the study here, which began in June, said Dr Zhong. A third recruitment site, KK Women's and Children's Hospital, is also in the works. As at July 12, there have been 2,816 dengue cases recorded here in 2025, according to figures from the National Environment Agency (NEA). In May, NEA noted that the number of dengue cases recorded here between January and May 2025 has dropped by about 74 per cent from the same period in 2024. Worldwide, the study aims to enrol about 12,000 healthy children, also between the ages of two and 17, who will receive either a single dose of V181 or a placebo. It aims to include more than 30 trial sites in dengue endemic areas in the Asia-Pacific, including Indonesia, Malaysia and the Philippines. Developing effective dengue vaccines has been difficult as the four serotypes are effectively four different viruses, said Prof Chia. While getting infected by one serotype grants lifelong protection against that particular strain, it provides only short-term protection against the other three, she said. This short-term protection eventually wanes, she noted, adding that those who contract dengue more than once risk antibody-dependent enhancement – a phenomenon where antibodies that are generated due to a vaccine or prior infection actually increase the severity of an infection. Dr Zhong noted this can result in dengue shock syndrome, otherwise known as dengue haemorrhagic fever, a potentially life-threatening complication with symptoms including circulatory failure. Designing a dengue vaccine has been challenging as it has to take into account this phenomenon, Prof Chia said. Should the trials be successful and the vaccine meet regulatory requirements, V181 could be commercially available as early as within the next three to five years, said Dr Zhong. Dr Paula Annunziato, senior vice-president for infectious diseases and vaccines global clinical development at MSD Research Laboratories, noted that half the world's population live in areas at risk for dengue. 'If successful, V181 could provide an important single-dose option for at-risk populations, regardless of previous exposure to dengue, to help reduce the significant burden around the globe,' she said. Dengvaxia, developed by Sanofi Pasteur, is currently the only dengue vaccine approved for use in Singapore. However, it is available only for those between 12 and 45 years old who have previously been infected and poses an increased risk of causing severe dengue in those who have never been infected. In May 2024, another quadrivalent vaccine, Qdenga, received pre-qualification from the World Health Organisation (WHO) – a process that aims to ensure the safety and efficacy of treatments – with WHO recommending the vaccine's use for children aged between six and 16 in dengue-prone areas. Developed by Japanese pharmaceutical company Takeda, Qdenga was made available in Malaysia in June 2024 . Qdenga was submitted for approval here in 2022. However, the following year, the Health Sciences Authority said Takeda had withdrawn its application. The authority said then that the company could submit another application with further clinical data on the vaccine meeting the 'required safety, efficacy and quality standards for use locally'.
